Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
P/B ratio for Phathom Pharmaceuticals, Inc. (PHAT)
P/B ratio as of 2023: -6.44
According to Phathom Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -6.44. At the end of 2022 the company had a P/B ratio of -5.87.
P/B ratio history for Phathom Pharmaceuticals, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -6.44 |
| 2022 | -5.87 |
| 2021 | 10.09 |
| 2020 | 5.68 |
| 2019 | 3.38 |
| 2018 | -164.09 |